Seizalam® (midazolam hydrochloride injection)
Seizalam is a benzodiazepine indicated for the treatment of status epilepticus in adults and FDA approved for people exposed to chemicals that cause prolonged seizures.
Availability: Commercially Available
| Manufacturer |
| Meridian Medical Technologies, Inc. |
| Product Name |
| Seizalam® (midazolam hydrochloride injection) |
| Detection Category |
| Chemical |
| Detection Method |
| Medical Countermeasure |
| Application |
| Personal Protective Equipment; |
| Equipment Type |
| PPE |
| Product Synopsis |
| Seizalam is a benzodiazepine indicated for the treatment of status epilepticus in adults and FDA approved for people exposed to chemicals that cause prolonged seizures. |
| Availability |
| Commercially Available |
| Technology Readiness Level (TRL) |
| 9 |
| Market Entry Date |
| 2018 |
| User Feedback Sources |
| Indifferent/No user feedback |
| Weight |
| <1 lb. |
| Power Requirements |
| None |
| Transportability |
| Pocket Size |
| Live Agent Tested |
| Yes |
| Material |
| 50 mg/10 mL (5 mg/mL) of a sterile, clear, colorless to light yellow liquid solution in a multiple-dose vial. |
| Operating Time |
| Immediate post-exposure use |
| Standards Met |
| FDA |
| Other Operational Parameters |
| Seizalam is for intramuscular use only. Inject in the mid-outer thigh (vastus lateralis muscle). |
| Training Required |
| <1 hour training |
| Manuals Available |
| Yes |
